ImmunoServ wins the St David Award 2025 for Innovation, Science and Technology

Cardiff Medicentre based biotech company ImmunoServ has been named the winner in the Innovation, Science and Technology category at the St David Awards 2025 – the national awards of Wales.

ImmunoServ, which was founded in 2020 by Cardiff University Research Fellow Dr Martin Scurr, alongside Immunology Theme Lead at Cardiff University’s School of Medicine, Professor Andrew Godkin, have devised kits for T cell testing that can indicate how protected people are from infectious diseases. Their expanding range of T cell testing products and services supports several public health bodies and research institutes providing significant insight into immunity to several diseases including COVID-19, seasonal flu, bird flu, Group A Streptococcus, as well as improving the diagnosis and treatment of diseases such as multiple sclerosis and cancer.

Now in their 12th year, the St David Awards celebrate outstanding individuals and organisations across Wales, recognising achievements in volunteering, bravery, business, community, and more. Other winners of this year’s award include TV drama production company Bad Wolf Ltd, Environmentalist Peter Stanley, Olympic Track Cyclist Emma Finucane MBE, and actress and TV writer Ruth Jones who won the First Minister’s Special Award.

After receiving the award from the First Minister for Wales, Eluned Morgan MS, ImmunoServ CEO and Cardiff University Alumni Dr James Hindley said: “The achievements of others in the Senedd were inspirational. I couldn’t be prouder of the ImmunoServ team to be recognised alongside them. Our hard work and dedication continue to drive innovation in immune monitoring. We’re also deeply thankful for the support we’ve received from organisations like Cardiff University, Cotton Mouton Diagnostics, MediWales, and the Welsh Government over the years. “

Martin Scurr, ImmunoServ CSO, added: “We are incredibly grateful to everyone who has played a role in ImmunoServ’s success—our scientific collaborators, our customers, and the amazing individuals who take part in our research. Their support continues to help us grow and flourish.”

In 2021, ImmunoServ launched their Immuno-T Test Kit, which uses tiny fragments of the virus or bacteria of interest to see if blood contains T cells that protect against the disease. The blood test can monitor a person’s immune response after infection or vaccination. The world's first at-home COVID-19 Immuno-T test is available to anyone in the UK who wishes to test their own T cell immunity. The company’s test can also measure immunity in large cohorts and population studies and enables standardised and scalable T cell testing to be performed in any laboratory throughout the world.

ImmunoServ are based at Cardiff University’s MediCentre, our specialist biotech and medtech incubation hub, set in the grounds of University Hospital of Wales. They occupy >1000 square feet of laboratory and office space, which is home to a seven-strong team of immunologists, including five PhD-level scientists.

Rhys Pearce-Palmer, Innovation Manager at Cardiff Medicentre, said: "On behalf of Cardiff Medicentre we are thrilled to see ImmunoServ recognised for their important work. ImmunoServ are an inspiring example of a company that draws strength from links with clinical practice and academia. We're proud to provide a strategic location next to the University Hospital of Wales and Cardiff University where companies like ImmunoServ can nurture collaborations which help to drive innovation."